InMed Pharmaceuticals

Name

InMed Pharmaceuticals

Legal name

InMed Pharmaceuticals Inc.

Website

https://inmedpharma.com

Company type

Public

Founded year

1981

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Headache & Migraine Medicine (HLAKAIAE)

Keywords

• Cannabinoid pharmaceutical development
• Alzheimer's drug research
• Clinical-stage biotechnology
• Rare cannabinoid manufacturing
• Migraine therapy development

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development: Revenue generation through development of drug candidates targeting Alzheimer's disease (INM-901), dry AMD (INM-089), and migraine prevention (via Mentari Therapeutics merger MT-001, MT-002). Currently pre-revenue as all programs are in preclinical/clinical stage.
2. BayMedica Commercial Cannabinoid Sales: Commercial sales of rare, non-intoxicating cannabinoids through BayMedica subsidiary to the health and wellness sector. Revenue declining 26% YoY to $0.8M in Q2 FY2026. Operations being wound down by June 30, 2026 due to U.S. legislation H.R. 5371.
3. Capital Markets / Private Placements: Revenue through capital raises including private placements, registered direct offerings, and at-the-market share offerings to fund pipeline development and operations. Major transactions include $6M (Sept 2022), $5M (June 2022), $12M (July 2021), and $290M private placement for Mentari merger (May 2026).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.

Product overview

InMed Pharmaceuticals is a pharmaceutical company focused on drug development for high unmet medical needs. The company's core pipeline includes INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. Through its subsidiary BayMedica (acquired September 2021), it previously manufactured rare cannabinoids for health and wellness, though this commercial segment is being wound down by June 2026. The company has announced a merger with Mentari Therapeutics to add migraine prevention candidates MT-001 and MT-002 to its portfolio. InMed historically developed small molecule drug candidates targeting CB1/CB2 receptors.

Differentiator

Problem solved

Functional benefit

Products and services

• INM-901 INM-901 is a proprietary drug candidate for Alzheimer's disease targeting neuroinflammation via the endocannabinoid system (CB1/CB2 receptors). Preclinical data in 3D human brain organoid models and animal studies demonstrate dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, with neuroprotection, neuritogenesis, and behavioral improvements. Pharmacokinetic studies showed robust bioavailability with no adverse neurological effects in large animal models.
• INM-089 INM-089 is a drug candidate for the treatment of dry age-related macular degeneration (dry AMD), addressing an unmet medical need where no approved disease-modifying therapies currently exist. The candidate is advancing toward a pre-IND meeting with the FDA in Q4 2026.
• SVN-SDN-14 Series Compounds The SVN-SDN-14 series consists of patent-pending small molecule drug candidates targeting the endocannabinoid system with demonstrated antidepressant-like activity benchmarked against fluoxetine (Prozac), supporting potential therapeutic applications for patients with inadequate SSRI response.
• MT-001 (post-Mentari merger) MT-001 is an anti-PACAP antibody targeting migraine prevention through a mechanism distinct from the CGRP pathway, addressing unmet need in patients who respond suboptimally to existing approved therapies. Regulatory filing is planned for mid-2026.
• MT-002 (post-Mentari merger) MT-002 is an anti-CGRP x PACAP bispecific antibody for migraine prevention, designed to address patients who respond suboptimally to current approved therapies by targeting both pathways simultaneously. Regulatory filing is planned for Q1 2027.
• BayMedica Rare Cannabinoids BayMedica is a wholly owned subsidiary of InMed Pharmaceuticals that manufactured and sold rare, non-intoxicating cannabinoids for the health and wellness sector using proprietary processes. Commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. federal legislation H.R. 5371; revenue was $0.8M in Q2 FY2026, declining 26% YoY.

Quantifiable outcome

• INM-901 demonstrated dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers in 3D human brain organoid models
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Mentari TherapeuticscoreStrategic or Co-development Partner · 1 May 2026InMed entered into a definitive all-stock merger agreement with Mentari Therapeutics in May 2026. The merger combines Mentari's migraine prevention drug pipeline (MT-001 anti-PACAP antibody, MT-002 anti-CGRP x PACAP bispecific) with InMed's public market infrastructure. The combined entity operates as Mentari Therapeutics on Nasdaq with approximately $421.4 million pro forma equity value.
• Stem Pharm, Inc.coreTechnology or Integration · 1 March 2026InMed collaborated with Stem Pharm, Inc. for preclinical validation studies using 3D human brain organoid models to demonstrate INM-901's reduction of neuroinflammation in Alzheimer's disease models. The studies showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, aligning with prior animal model findings.
• BayMedicacoreStrategic or Co-development Partner · 1 September 2021InMed Pharmaceuticals acquired BayMedica, a US-based company specializing in manufacturing rare cannabinoids, in September 2021. The acquisition aimed to position InMed as a global leader in cannabinoid manufacturing and expand its product pipeline with high-value cannabinoid products. BayMedica's commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. legislation H.R. 5371.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Axsome Therapeutics: Clinical-stage-to-commercial CNS specialty pharma with FDA-approved migraine therapy Qulipta (CGRP antagonist) and Auvelity for depression — directly comparable to InMed/Mentari's CNS pipeline focus and indication overlap.
• Tonix Pharmaceuticals: Clinical-stage CNS company developing migraine therapies and other neurological candidates, with comparable small-cap profile and pipeline-stage risk/reward similar to InMed/Mentari.
• Biohaven Pharmaceuticals: Migraine-focused specialty pharma (Nurtec ODT) and CNS pipeline developer — directly comparable therapeutic focus and development stage for the post-merger Mentari migraine assets.
• Sage Therapeutics: CNS specialty pharma with depression and neurology pipeline (Zurzuvae) — comparable clinical-stage CNS drug developer with similar indication overlap to InMed's neurology programs.
• Aelis Farma: Cannabinoid-based pharmaceutical developer focused on CNS disorders, with a CB1-targeting platform — directly comparable mechanism and therapeutic focus to InMed's cannabinoid approach.

Broad incumbents

• Jazz Pharmaceuticals: Specialty pharma with Epidiolex (cannabidiol) and a CNS franchise including migraine therapy — established player with overlapping cannabinoid-pharma and migraine therapeutics comparable to InMed/Mentari's pipeline.
• Lundbeck: Specialty pharma with strong neurology/migraine franchise (Vyepti anti-CGRP) — direct therapeutic-area incumbent comparable to the migraine focus of post-merger pipeline.
• AbbVie: Large pharma with migraine franchise (Ubrelvy CGRP antagonist) and neurology pipeline — comparable therapeutic area and potential strategic acquirer of CNS assets like InMed/Mentari's pipeline.
• Pfizer: Large pharma with migraine asset (Nurtec ODT) via Biohaven acquisition and active CNS investing — comparable migraine therapeutic exposure and potential partnership/acquisition counterparty.

Emerging players

• Corcept Therapeutics: Specialty CNS pharma focused on cortisol-modulating therapies with comparable small/mid-cap profile — comparable scale and commercial-stage CNS drug development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/inmedpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InMed Pharmaceuticals